Abstract:According to GLOBOCAN 2021 cancer incidence and mortality statistics compiled by the International Agency for Research on Cancer, hepatocellular carcinoma (HCC) is the most common malignancy in the human liver and one of the leading causes of cancer death worldwide. Although there have been great advances in the treatment of HCC, such as regofenib, sorafenib, and lomvatinib, which have been developed and approved for the clinical treatment of advanced or metastatic HCC. However, they only prolong survival by a few months, and patients with advanced liver cancer are susceptible to tumor invasion metastasis and drug resistance. Ubiquitination modification is a type of post-translational modification of proteins. It can affect the physiological activity of cells by regulating the localization, stability and activity of proteins, such as: gene transcription, DNA damage signaling and other pathways. The reversible process of ubiquitination is called de-ubiquitination: it is the process of re-releasing ubiquitinated substrates with the participation of de-ubiquitinases (DUBs) and other active substances. There is growing evidence that many dysregulations of DUBs are associated with tumorigenesis. Although dysregulation of deuquitinase function is often found in HCC and other cancers, The mechanisms of action of many DUBs in HCC have not been elucidated. In this review, we focused on several deubiquitinases (DUBs) associated with hepatocellular carcinoma, including their structure, function, and relationship to hepatocellular carcinoma. hepatocellular carcinoma was highlighted, as well as the latest research reports. Among them, we focus on the USP family and OTU family which are more studied in the HCC. In addition, we discussed the prospects and significance of targeting DUBs as a new strategy for the treatment of hepatocellular carcinoma. It also briefly summarizes the research progress of some DUB-related small molecule inhibitors and their clinical application significance as a treatment for HCC in the future.

Regulation of apoptosis by ubiquitination in liver cancer

Over-expression of Ubiquitin Carboxy Terminal Hydrolase-L1 Induces Apoptosis in Breast Cancer Cells.

Ubiquitin at the crossroad of cell death and survival.

Research Progress of DUB Enzyme in Hepatocellular Carcinoma

The Ubiquitin-Proteasome System in Apoptosis and Apoptotic Cell Clearance

Role of Ubiquitin-specific Proteases in Hepatocellular Carcinoma Pathogenesis

Emerging Role of DUBs in Tumor Metastasis and Apoptosis: Therapeutic Implication

Killing by Degradation: Regulation of Apoptosis by the Ubiquitin-Proteasome-System

Ubiquitin carboxyl-terminal hydrolases: involvement in cancer progression and clinical implications

Roles and regulation of histone acetylation in hepatocellular carcinoma

The Multiple Roles of Deubiquitinases in Liver Cancer.

Ubiquitination of Nonhistone Proteins in Cancer Development and Treatment

The roles of E3 ubiquitin ligases in cancer progression and targeted therapy

Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches

USP53 Plays an Antitumor Role in Hepatocellular Carcinoma Through Deubiquitination of Cytochrome C

URM1 Promoted Tumor Growth and Suppressed Apoptosis via the JNK Signaling Pathway in Hepatocellular Carcinoma

Aberrant Regulation of Wnt Signaling in Hepatocellular Carcinoma

Ubiquitin-like proteins and hepatocellular carcinoma

Programmed cell death in hepatocellular carcinoma: mechanisms and therapeutic prospects

Role of Ubiquitin Regulatory X Domain‑containing Protein 3B in the Development of Hepatocellular Carcinoma (Review)

Targeting the Ubiquitin Pathway for Cancer Treatment